PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.13%
EBIT growth above 1.5x AXSM's 2.93%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
37.34%
Operating income growth above 1.5x AXSM's 2.93%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
47.13%
Positive net income growth while AXSM is negative. John Neff might see a big relative performance advantage.
50.90%
Positive EPS growth while AXSM is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
52.86%
Positive diluted EPS growth while AXSM is negative. John Neff might view this as a strong relative advantage in controlling dilution.
7.67%
Share reduction more than 1.5x AXSM's 39.33%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
12.32%
Diluted share reduction more than 1.5x AXSM's 39.33%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
33.57%
OCF growth above 1.5x AXSM's 8.75%. David Dodd would confirm a clear edge in underlying cash generation.
33.08%
FCF growth above 1.5x AXSM's 8.60%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9761.92%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-7404.36%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-3986.05%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-11268.60%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-11424.82%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
97.34%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
7616.79%
Equity/share CAGR of 7616.79% while AXSM is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
547.30%
Equity/share CAGR of 547.30% while AXSM is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-8.66%
We have a declining book value while AXSM shows 138.85%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-100.00%
We’re deleveraging while AXSM stands at 38.77%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-26.31%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-49.44%
We cut SG&A while AXSM invests at 9.42%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.